Evaluating the Effect of Flaxseed on PCOS

Phase 3

Recruiting

• Conditions: poly-cystic ovarian syndrome.; Polycystic ovarian syndrome; E28.2

• Registration Number: IRCT20170916036204N8
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 24 March 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 84

Inclusion Criteria

Diagnosis of Polycystic Ovarian Syndrome Based on Rotterdam Criteria By clinical practitioner

Exclusion Criteria

Family history of breast, ovarian or uterine cancer
Alcohol or drug use
Pregnancy or lactation
Use of anti-hypertension and lipid lowering drugs
Metformin use 6 months before enrollment and during the study
Diabetes, thyroid disease or any systemic disease (eg kidney, liver, digestive system, cardiovascular)
Other disorders that lead to increased androgens in the blood (such as Cushing's syndrome, hyper prolactinemia)
Menopause
Use of drugs that affect glucose metabolism

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
?Fasting Blood Sugar. Timepoint: At the beginning and the end of the study (after 8 weeks ). Method of measurement: FBS kit.;Insulin. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Insulin kit.

Secondary Outcome Measures

Name	Time	Method
uteinizing Hormone. Timepoint: At the beginning and the end of the study (after 8 weeks ). Method of measurement: Luteinizing Hormone kit.;Follicle-Stimulating Hormone. Timepoint: At the beginning and the end of the study (after 8 weeks ). Method of measurement: Follicle-Stimulating Hormone kit.